The antifungal drug clotrimazole (CTM) has an uncertain future with respect to treatment of the systemic mycoses. To explore further the chemotherapeutic potential of this drug, the authors have been studying in vitro effects of low level CTM in combination with other drugs against Candida species. Results with CTM and sulfamethoxazole (SMX) are presented here. A subinhibitory concentration of SMX (50 μg./ml.) in combination with a weak inhibitory level of CTM (1.0 μg./ml.) exerted marked fungistatic effects on 4 different strains of Candida albicans. Combined activity exceeded that of CTM alone and was interpreted as drug synergism. Similar results were obtained with strains of Candida tropicalis and Candida parapsilosis.
|Original language||English (US)|
|Number of pages||7|
|Journal||Current Therapeutic Research - Clinical and Experimental|
|Issue number||4 II|
|State||Published - Jan 1 1976|